IDEAYA Biosciences (IDYA) Payables (2018 - 2026)

IDEAYA Biosciences has reported Payables for 9 years, with the latest figure at $20.7 million in Q1 2026.

• Quarterly Payables rose 17.61% year-over-year to $20.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.7 million (up 17.61% YoY) and the FY2025 annual result came in at $17.6 million, up 14.03% from the prior year.
• Payables improved to $20.7 million in Q1 2026 per IDYA's latest filing, from $17.6 million in the prior quarter.
• Over five years, Payables peaked at $20.7 million in Q1 2026 and troughed at $3.4 million in Q1 2022.
• A 5-year average of $10.5 million and a median of $6.6 million in 2023 frame the typical range for Payables.
• The widest YoY moves for Payables: up 180.3% in 2025, down 8.71% in 2025.
• Over 5 years, Payables stood at $4.3 million in 2022, then surged by 54.16% to $6.6 million in 2023, then jumped by 133.72% to $15.4 million in 2024, then gained by 14.03% to $17.6 million in 2025, then increased by 17.93% to $20.7 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $20.7 million, $17.6 million, and $18.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.